Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells.

Alsaieedi A, Holler A, Velica P, Bendle G, Stauss HJ.

Oncoimmunology. 2018 Dec 5;8(3):1542917. doi: 10.1080/2162402X.2018.1542917. eCollection 2019.

2.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK.

Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013. Epub 2018 Aug 16.

3.

Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.

Hotblack A, Holler A, Piapi A, Ward S, Stauss HJ, Bennett CL.

Mol Ther. 2018 Jun 6;26(6):1471-1481. doi: 10.1016/j.ymthe.2018.03.011. Epub 2018 Mar 16.

4.

Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity.

Hou TZ, Olbrich P, Soto JML, Sanchez B, Moreno PS, Borte S, Stauss HJ, Burns SO, Walker LSK, Pan-Hammarström Q, Hammarström L, Sansom DM, Neth O.

Clin Immunol. 2018 Mar;188:94-102. doi: 10.1016/j.clim.2018.01.001. Epub 2018 Jan 3.

PMID:
29305966
5.

Engineering Specificity and Function of Therapeutic Regulatory T Cells.

McGovern JL, Wright GP, Stauss HJ.

Front Immunol. 2017 Nov 10;8:1517. doi: 10.3389/fimmu.2017.01517. eCollection 2017. Review.

6.

No hiding place for BOB inside myeloma.

Stauss HJ.

Blood. 2017 Mar 9;129(10):1236-1237. doi: 10.1182/blood-2017-01-761510. No abstract available.

7.

Turn to TCRs when CARs fail.

Stauss HJ.

Oncotarget. 2017 Feb 21;8(8):12538-12539. doi: 10.18632/oncotarget.15088. No abstract available.

8.

Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype.

Geerdink JX, Simons SO, Pike R, Stauss HJ, Heijdra YF, Hurst JR.

Respir Res. 2016 Oct 28;17(1):140.

9.

Optimizing T-cell receptor gene therapy for hematologic malignancies.

Morris EC, Stauss HJ.

Blood. 2016 Jun 30;127(26):3305-11. doi: 10.1182/blood-2015-11-629071. Epub 2016 May 20. Review.

10.

PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.

Pike R, Thomas N, Workman S, Ambrose L, Guzman D, Sivakumaran S, Johnson M, Thorburn D, Harber M, Chain B, Stauss HJ.

Front Immunol. 2016 Apr 11;7:126. doi: 10.3389/fimmu.2016.00126. eCollection 2016.

11.

Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.

Holler A, Zech M, Ghorashian S, Pike R, Hotblack A, Veliça P, Xue SA, Chakraverty R, Morris EC, Stauss HJ.

Haematologica. 2016 Apr;101(4):482-90. doi: 10.3324/haematol.2015.132712. Epub 2016 Jan 22.

12.

Cancer gene therapy with T cell receptors and chimeric antigen receptors.

Stauss HJ, Morris EC, Abken H.

Curr Opin Pharmacol. 2015 Oct;24:113-8. doi: 10.1016/j.coph.2015.08.006. Epub 2015 Sep 4. Review.

PMID:
26342910
13.

Engineered T cells can fight malignant T cells.

Stauss HJ.

Blood. 2015 Aug 20;126(8):927-8. doi: 10.1182/blood-2015-07-652057.

14.

T cell tuning for tumour therapy: Enhancing effector function and memory potential of therapeutic T cells.

Zech MH, Velica P, Stauss HJ.

Curr Gene Ther. 2015;15(3):289-99. Review.

PMID:
25619883
15.

CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.

Ghorashian S, Veliça P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA, Uckert W, Morris E, Chakraverty R, Stauss HJ.

J Immunol. 2015 Feb 1;194(3):1080-9. doi: 10.4049/jimmunol.1401703. Epub 2014 Dec 24.

16.

Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.

Stauss HJ, Morris EC.

Gene Ther. 2013 Nov;20(11):1029-32. doi: 10.1038/gt.2013.34. Epub 2013 Jun 27. Review.

PMID:
23804078
17.

Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.

Xue SA, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ.

Oncoimmunology. 2013 Jan 1;2(1):e22590.

18.

Challenges in T cell receptor gene therapy.

Uttenthal BJ, Chua I, Morris EC, Stauss HJ.

J Gene Med. 2012 Jun;14(6):386-99. doi: 10.1002/jgm.2637. Review.

PMID:
22610778
19.

Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA, Steven NM, Willcox BE.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21176-81. doi: 10.1073/pnas.1108422109. Epub 2011 Dec 12.

20.

T cell gene-engineering to enhance GVT and suppress GVHD.

Ghorashian S, Nicholson E, Stauss HJ.

Best Pract Res Clin Haematol. 2011 Sep;24(3):421-33. doi: 10.1016/j.beha.2011.05.004. Epub 2011 Jun 28. Review.

PMID:
21925095
21.

Therapeutic potential of Tregs to treat rheumatoid arthritis.

Wright GP, Stauss HJ, Ehrenstein MR.

Semin Immunol. 2011 Jun;23(3):195-201. doi: 10.1016/j.smim.2011.07.004. Epub 2011 Aug 30. Review.

PMID:
21880506
22.

CD3 limits the efficacy of TCR gene therapy in vivo.

Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ.

Blood. 2011 Sep 29;118(13):3528-37. doi: 10.1182/blood-2011-04-346338. Epub 2011 Jul 12.

23.

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ.

Blood. 2011 Jul 14;118(2):319-29. doi: 10.1182/blood-2010-12-326736. Epub 2011 May 23.

24.

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.

Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, Mitchison NA.

Cancer Immunol Immunother. 2011 Aug;60(8):1127-35. doi: 10.1007/s00262-011-0985-7. Epub 2011 Apr 9. Review.

PMID:
21479639
25.

Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination.

Pospori C, Xue SA, Holler A, Voisine C, Perro M, King J, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC.

Blood. 2011 Jun 23;117(25):6813-24. doi: 10.1182/blood-2010-08-304568. Epub 2011 Mar 29.

26.

Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.

Wright GP, Ehrenstein MR, Stauss HJ.

Expert Rev Clin Immunol. 2011 Mar;7(2):213-25. doi: 10.1586/eci.10.96. Review.

PMID:
21426259
27.

Molecular immunology lessons from therapeutic T-cell receptor gene transfer.

Thomas S, Stauss HJ, Morris EC.

Immunology. 2010 Feb;129(2):170-7. doi: 10.1111/j.1365-2567.2009.03227.x. Review.

28.

Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis.

Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, Ehrenstein MR, Stauss HJ.

Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19078-83. doi: 10.1073/pnas.0907396106. Epub 2009 Nov 2.

29.

Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors.

Dai MS, Nitcheu-Tefit J, Alcock S, Ramirez-Jimenez F, Chao TY, Baril P, Rocha M, Brett SJ, Stauss HJ, Vassaux G.

J Immunother. 2009 Oct;32(8):845-55. doi: 10.1097/CJI.0b013e3181aee259.

PMID:
19752749
30.

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.

Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ.

Haematologica. 2010 Jan;95(1):126-34. doi: 10.3324/haematol.2009.006486. Epub 2009 Aug 13.

31.

Immunomodulation in the treatment of haematological malignancies.

Cesco-Gaspere M, Morris E, Stauss HJ.

Clin Exp Med. 2009 Jun;9(2):81-92. doi: 10.1007/s10238-009-0037-1. Epub 2009 Feb 24. Review.

PMID:
19238515
32.

IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.

King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, Pigott K, Kaisary A, Stauss HJ, Waxman J.

Clin Cancer Res. 2009 Feb 15;15(4):1145-54. doi: 10.1158/1078-0432.CCR-08-1821.

33.

Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.

Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, Stauss HJ, Bucy RP, Lombardi G, Lechler R.

J Clin Invest. 2008 Nov;118(11):3619-28. doi: 10.1172/JCI33185. Epub 2008 Oct 9.

34.

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.

Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK.

Blood. 2008 Oct 1;112(7):2956-64. doi: 10.1182/blood-2008-02-137695. Epub 2008 May 23.

35.

Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.

Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ.

Gene Ther. 2008 Apr;15(8):625-31. doi: 10.1038/sj.gt.3303078. Epub 2008 Feb 28.

PMID:
18305579
36.

Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2.

Xue SA, Bendle GM, Holler A, Stauss HJ.

Immunology. 2008 Jul;124(3):315-21. doi: 10.1111/j.1365-2567.2007.02793.x. Epub 2008 Jan 24.

37.

Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.

Thomas S, Xue SA, Cesco-Gaspere M, San José E, Hart DP, Wong V, Debets R, Alarcon B, Morris E, Stauss HJ.

J Immunol. 2007 Nov 1;179(9):5803-10.

38.

WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.

Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6. Epub 2007 Sep 12. Review.

PMID:
17855129
39.

T-cell receptor gene therapy for cancer: the progress to date and future objectives.

Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1207-18. Review.

PMID:
17696819
40.

Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.

Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, Ferry N, Stauss HJ, Vassaux G.

J Immunol. 2007 Aug 1;179(3):1532-41.

41.

Monoclonal T-cell receptors: new reagents for cancer therapy.

Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A, Wright G, Perro M, Little AM, Pospori C, King J, Morris EC.

Mol Ther. 2007 Oct;15(10):1744-50. Epub 2007 Jul 17. Review.

42.

Enhancing immune responses for cancer therapy.

Xue SA, Stauss HJ.

Cell Mol Immunol. 2007 Jun;4(3):173-84. Review.

43.

CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR.

McNicol AM, Bendle G, Holler A, Matjeka T, Dalton E, Rettig L, Zamoyska R, Uckert W, Xue SA, Stauss HJ.

Eur J Immunol. 2007 Jun;37(6):1634-41.

45.

Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.

Gillmore R, Xue SA, Holler A, Kaeda J, Hadjiminas D, Healy V, Dina R, Parry SC, Bellantuono I, Ghani Y, Coombes RC, Waxman J, Stauss HJ.

Clin Cancer Res. 2006 Jan 1;12(1):34-42.

46.

Antigen-specific cellular immunotherapy of leukemia.

Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF.

Leukemia. 2005 Nov;19(11):1863-71. Review.

PMID:
16121214
47.

Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.

Bendle GM, Holler A, Downs AM, Xue SA, Stauss HJ.

Expert Opin Biol Ther. 2005 Sep;5(9):1183-92. Review.

PMID:
16120049
48.

Regulatory T cells, derived from naïve CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance.

Chai JG, Xue SA, Coe D, Addey C, Bartok I, Scott D, Simpson E, Stauss HJ, Hori S, Sakaguchi S, Dyson J.

Transplantation. 2005 May 27;79(10):1310-6.

PMID:
15912097
49.

A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7934-9. Epub 2005 May 20.

50.

Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, Larkin DF, McClure MO, Stauss HJ, Ritter MA, Lombardi G, George AJ.

Blood. 2005 May 15;105(10):3824-32. Epub 2005 Jan 25.

Supplemental Content

Loading ...
Support Center